FURTHER ALLIANCE PHARMA PLC INVESTMENT

The “Further Alliance Pharma plc Investment” announcement published at 13:28 on 23 February 2023 (RNS Number 8890Q) erroneously stated the additional shares purchased as 18,686,042, being the resultant holding, instead of 5,841,042. All other details remain unchanged.

The full corrected announcement is provided below.

23 February 2023

LDG plc

(“LDG”) or the "Company")

Further Alliance Pharma plc Investment

LDG is pleased to announce that, further to its announcement on 22 December 2022, it has purchased an additional 5,841,042 ordinary shares in Alliance Pharma plc ("Alliance") (LON:APH), at an average price of £0.5911 per ordinary share, for a total cash consideration of £3,452,782.

Following these purchases, LDG is interested in 18,686,042 Alliance ordinary shares, representing approximately 3.46% of Alliance’s issued share capital.

Alliance is an international healthcare group founded in 1996 and headquartered in the United Kingdom. The company acquires, markets, and distributes consumer healthcare and prescription medicine products.

For the year ended 31 December 2021, Alliance reported an underlying pre-tax profit of £42.2 million. As at 30 June 2022, Alliance reported net assets of £296.9 million.

For enquiries:

LDG plc via FTI Consulting

FTI Consulting
Nick Hasell
Alex Le May
Cally Billimore
+44 (0) 20 3727 1340

Strand Hanson Limited (Financial and Nominated Adviser)
James Spinney
James Dance
Abigail Wennington
+44 (0) 20 7409 3494

Investec Bank plc (Broker)
Gary Clarence
Harry Hargreaves
+44 (0) 20 7597 5970